Figure 6.

Therapy-treated OB-RES mice have a sustained CD8⁺ TIL effector response that is blunted in DIO mice. (A) CD44⁺CD8⁺ TILs at day 17–18, day 21, and day 27–28 post-tumor challenge across groups. (B) Linear regression of CCL5 concentrations versus CD44⁺CD8⁺ TILs at day 21 post-tumor challenge. (C) The frequencies of CD11b^—CD11c⁺I-A^d+ TDLN DCs and (D) CD86 expression on TDLN CD11b^—CD11c⁺I-A^d+ DCs; (E) the frequencies of TDLN CD44⁺CD8⁺ T cells and (F) the proliferative capacity (Ki-67⁺) in TDLN CD44⁺CD8⁺ T cells at days 17–18 post-tumor challenge. (G) Cell viability and death markers at day 21 post-tumor challenge in CD44⁺CD8⁺ TILs. (H) Intracellular expression of IFNγ and (I) the mean fluorescent intensity of IFNγ in ex vivo stimulated CD44⁺CD8⁺ TILs at day 21 post-tumor challenge. (J) IFNγ⁺CD44⁺CD8⁺ TILs as a percent of single cells at day 21 post-tumor challenge. Data from n = 2–5 independent experiments. Fold change value calculated using no therapy control for each group. ^# denotes non-parametric test. ^# p < 0.05, ^## p < 0.01, ^### p < 0.001, ^#### p < 0.0001. ns: non-significant, NT: no therapy, TX: AdT/CpG+αCTLA-4.